866-997-4948(US-Canada Toll Free)

Secondary Hyperparathyroidism - Pipeline Review, H1 2019

Published By :

Global Markets Direct

Published Date : Jan 2019

Category :

Pharmaceutical

No. of Pages : 58 Pages

Secondary Hyperparathyroidism - Pipeline Review, H1 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Secondary Hyperparathyroidism - Pipeline Review, H1 2019, provides an overview of the Secondary Hyperparathyroidism (Hormonal Disorders) pipeline landscape.

Secondary hyperparathyroidism is occurs when the parathyroid glands in neck produce too much parathyroid hormone (PTH) because calcium levels are too low. Symptoms include bone deformities, broken bones, swollen joints and chronic kidney failure. Treatment includes calcimimetic and hormone replacement therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Secondary Hyperparathyroidism - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Secondary Hyperparathyroidism (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Secondary Hyperparathyroidism (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Secondary Hyperparathyroidism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 2, 3 and 2 respectively.

Secondary Hyperparathyroidism (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Secondary Hyperparathyroidism (Hormonal Disorders).
- The pipeline guide reviews pipeline therapeutics for Secondary Hyperparathyroidism (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Secondary Hyperparathyroidism (Hormonal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Secondary Hyperparathyroidism (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Secondary Hyperparathyroidism (Hormonal Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Secondary Hyperparathyroidism (Hormonal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Secondary Hyperparathyroidism (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Secondary Hyperparathyroidism - Overview
Secondary Hyperparathyroidism - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Secondary Hyperparathyroidism - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Secondary Hyperparathyroidism - Companies Involved in Therapeutics Development
Amgen Inc
EA Pharma Co Ltd
Lupin Ltd
Mitsubishi Tanabe Pharma Corp
OPKO Health Inc
Takeda Pharmaceutical Co Ltd
Secondary Hyperparathyroidism - Drug Profiles
AJT-240 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
calcifediol ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cinacalcet - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cinacalcet hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTA-091 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Dendocrin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
etelcalcetide hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
evocalcet - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LNP-1892 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VS-105 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Secondary Hyperparathyroidism - Dormant Projects
Secondary Hyperparathyroidism - Discontinued Products
Secondary Hyperparathyroidism - Product Development Milestones
Featured News & Press Releases
Sep 04, 2018: OPKO initiates RAYALDEE phase 2 trial in dialysis patients
Jul 16, 2018: OPKO Partner Vifor Fresenius Receives Marketing Approval for RAYALDEE in Canada
May 22, 2018: Kyowa Hakko Kirin Launches ORKEDIA TABLETS (Evocalcet) for the Treatment of Secondary Hyperparathyroidism in Patients on Maintenance Dialysis in Japan
Mar 23, 2018: Kyowa Hakko Kirin Receives Approval for ORKEDIA Tablets (Evocalcet) for the Treatment of Secondary Hyperparathyroidism in Patients on Maintenance Dialysis in Japan
Nov 06, 2017: Kyowa Hakko Kirin Presented Results of Japan Phase III Clinical Study of Evocalcet at Kidney Week 2017 of the American Society of Nephrology
Aug 31, 2017: European Commission Approves Expanded Use Of Mimpara (Cinacalcet) For The Treatment Of Secondary Hyperparathyroidism In Children With End-Stage Renal Disease On Dialysis
Jun 23, 2017: Amgen Receives Positive CHMP Opinion To Expand Use Of Mimpara (cinacalcet) For The Treatment Of Secondary Hyperparathyroidism In Certain Children With End-Stage Renal Disease On Dialysis
Jun 22, 2017: OPKO Health Announces KDIGO Clinical Practice Guideline Update on CKD-MBD
Jun 05, 2017: OPKO Health Provides Commercial Update for RAYALDEE
Apr 27, 2017: Kyowa Hakko Kirin Submits Application for Approval of Evocalcet (KHK7580) for Secondary Hyperparathyroidism in Maintenance Dialysis Patients in Japan
Feb 15, 2017: Launch of PARSABIV Intravenous Injection for Dialysis, a Calcimimetic Agent, for Treatment of Secondary Hyperparathyroidism in Patients on Hemodialysis
Feb 07, 2017: OPKO Health Promotes Thomas Nusbickel to Renal Division Chief Commercial Officer
Feb 07, 2017: FDA Approves Amgen's Parsabiv (Etelcalcetide), First New Treatment In More Than A Decade For Secondary Hyperparathyroidism In Adult Patients On Hemodialysis
Jan 31, 2017: Kyowa Hakko Kirin Announces Top-Line Results of Phase 3 Clinical Study of KHK7580 with Secondary Hyperparathyroidism in Japan
Jan 10, 2017: Study Results Published in the Journal of the American Medical Association Show Amgen's Parsabiv (Etelcalcetide) Significantly Reduced Serum Parathyroid Hormone in Adults With Secondary Hyperparathyroidism on Hemodialysis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Secondary Hyperparathyroidism, H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Number of Products by Stage and Target, H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Secondary Hyperparathyroidism - Pipeline by Amgen Inc, H1 2019
Secondary Hyperparathyroidism - Pipeline by EA Pharma Co Ltd, H1 2019
Secondary Hyperparathyroidism - Pipeline by Lupin Ltd, H1 2019
Secondary Hyperparathyroidism - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2019
Secondary Hyperparathyroidism - Pipeline by OPKO Health Inc, H1 2019
Secondary Hyperparathyroidism - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2019
Secondary Hyperparathyroidism - Dormant Projects, H1 2019
Secondary Hyperparathyroidism - Discontinued Products, H1 2019

List of Figures
Number of Products under Development for Secondary Hyperparathyroidism, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products by Top 10 Targets, H1 2019
Number of Products by Stage and Top 10 Targets, H1 2019
Number of Products by Mechanism of Actions, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *